Reading view
Understanding the Application of Utility Theory in Robotics and Artificial Intelligence: A Survey
PaperArena: An Evaluation Benchmark for Tool-Augmented Agentic Reasoning on Scientific Literature
RoboGPT-R1: Enhancing Robot Planning with Reinforcement Learning
Development and validation of an integrative 54 biomarker-based risk identification model for multi-cancer in 42,666 individuals: a population-based prospective study to guide advanced screening strategies
Biomark Res. 2025 Aug 11;13(1):101. doi: 10.1186/s40364-025-00812-z.
ABSTRACT
BACKGROUND: Early identification of high-risk individuals is crucial for optimizing cancer screening, particularly when considering expensive and invasive methods such as multi-omics technologies and endoscopic procedures. However, developing a robust, practical multi-cancer risk prediction model that integrates diverse, multi-scale data and with proper validation remains a significant challenge.
METHODS: We initialized the FuSion study by recruiting 42,666 participants from Taizhou, China, with a discovery cohort (n = 16,340) and an independent validation cohort (n = 26,308) after exclusion criteria. We integrated multi-scale data from 54 blood-derived biomarkers and 26 epidemiological exposures to develop a risk prediction model for five common cancers, including lung, esophageal, liver, gastric, and colorectal cancer. Employing five supervised machine learning approaches, we used a LASSO-based feature selection strategy to identify the most informative predictors. The model was trained and internally validated in the discovery cohort, externally applied in the validation cohort, and further evaluated through a prospective clinical follow-up to assess cancer events via clinical examinations.
RESULTS: The final model comprising four key biomarkers along with age, sex, and smoking intensity, achieving an AUROC of 0.767 (95% CI: 0.723-0.814) for five-year risk prediction. High-risk individuals (17.19% of the cohort) accounted for 50.42% of incident cancer cases, with a 15.19-fold increased risk compared to the low-risk group. During follow-up of 2,863 high-risk subjects, 9.64% were newly diagnosed with cancer or precancerous lesions. Notably, cancer detection in the high-risk group was 5.02 times higher than in the low-risk group and 1.74 times higher than in the intermediate-risk group. In particular, the incidence of esophageal cancers in the high-risk group was 16.84 times that of the low-risk group.
CONCLUSIONS: This is the first population-based prospective study in a large Chinese cohort that leverage multi-scale data including biomarkers for multi-cancer risk prediction. Our effective risk stratification model not only enhances early cancer detection but also lays the foundation for the targeted application of advanced screening methods, including but not limited to multi-omics technologies and endoscopy. These findings support precision prevention strategies and the optimal allocation of healthcare resources.
PMID:40790537 | PMC:PMC12341305 | DOI:10.1186/s40364-025-00812-z
RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis
Cancer Lett. 2025 Jan 12;612:217462. doi: 10.1016/j.canlet.2025.217462. Online ahead of print.
ABSTRACT
A user-friendly integrated database, RMethyMD (http://www.tmliang.cn/rnamethy), was developed to provide a comprehensive analysis of methylation regulators aimed at facilitating the exploration of molecular features in tumorigenesis and clinical implications in cancer diagnosis and treatment via a multiomics approach. Subsequently, molecular landscapes and a robust constructed m6A-based prognostic model using coxBoost + RSF algorithms in lung cancer highlighted m6A as a suitable marker to guide therapeutic strategy. RMethyMD provides a comprehensive resource and multiomics analysis to explore m6A-based prognostic and clinical values, thereby contributing to aiding personalized cancer therapy.
PMID:39809358 | DOI:10.1016/j.canlet.2025.217462
LcProt: Proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study
Clin Transl Med. 2025 Jan;15(1):e70160. doi: 10.1002/ctm2.70160.
ABSTRACT
BACKGROUND: Plasma protein has gained prominence in the non-invasive predicting of lung cancer. We utilised Zeolite Zotero NaY-based plasma proteomics to investigate its potential for multiple event predicting, including lung cancer diagnosis (task #1), lymph node metastasis detection (task #2) and tumourβnodeβmetastasis (TNM) staging (task #3).
METHODS: A total of 4703 plasma proteins were quantified from 241 participants based on a prospective cohort of 2757 participants. An additional 46 participants from external prospective cohort of 735 participants were used for validation. Feature selection was performed using differential expressed protein analysis, area under curve (AUC) evaluation and least absolute shrinkage and selection operator (LASSO) regression. Random forest was used for multitask model construction based on the key proteins. Feature importance was interpreted using Shapley additive explanations (SHAP) algorithm.
RESULTS: For task #1, 10 proteins panel showed an AUC of .87 (.77β.97) in the external validation. After integrating clinical factors, a significant increase diagnostic accuracy was observed with AUC of .91 (.85β.98). For task #2, nine proteins panel achieved an AUC of .88 (.80β.96), integration model showed an increase diagnostic accuracy with AUC of .90 (.85β.97). For task #3, 10 proteins panel showed an AUC of .88 (.74β.96) for stage I, .92 (.84β.97) for stage II, .88 (.76β.96) for stage III and .99 (.98β.99) for stage IV in the integration model.
CONCLUSIONS: This study comprehensively profiled the NaY-based plasma proteome biomarker, laying the foundation for a high-performance blood test for predicting multiple events in lung cancer.
KEY POINTS: Our study developed an innovative nanomaterial, Zeolite NaY, which addressed the masking effect and improved the depth of the proteome. The performance of NaY-based plasma proteomics as a preclinical diagnostic tool was validated through both internal and external cohort. Furthermore, we explored the different patterns of plasma protein changes during the progression of lung cancer and used the explanations method to elucidate the roles of proteins in the multitask predictive model.
PMID:39783847 | PMC:PMC11714244 | DOI:10.1002/ctm2.70160